Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
Cassava Sciences (Nasdaq: SAVA), a clinical-stage biotechnology company focusing on Alzheimer's disease, has announced a conference call scheduled for Thursday, August 8th, 2024, at 8:30 a.m. Eastern Time. The call aims to discuss recent developments and provide a company update.
Interested parties can access the audio webcast through the company's website or via a direct link. A replay of the webcast will be available for 90 days following the event on Cassava Sciences' Company Presentations page.
This announcement suggests that Cassava Sciences may have significant updates to share regarding their Alzheimer's research or company progress, potentially impacting their stock performance.
Cassava Sciences (Nasdaq: SAVA), una compagnia di biotecnologie in fase clinica che si concentra su malattia di Alzheimer, ha annunciato una telefonata di conferenza programmata per giovedì 8 agosto 2024, alle 8:30 ora orientale. La chiamata ha lo scopo di discutere gli sviluppi recenti e fornire un aggiornamento sulla compagnia.
Le parti interessate possono accedere alla trasmissione audio tramite il sito web della società o tramite un link diretto. Una registrazione della trasmissione sarà disponibile per 90 giorni dopo l'evento nella pagina delle Presentazioni della Società di Cassava Sciences.
Questo annuncio suggerisce che Cassava Sciences potrebbe avere aggiornamenti significativi da condividere riguardo alla loro ricerca sull'Alzheimer o ai progressi aziendali, con potenziali ripercussioni sulle loro performance azionarie.
Cassava Sciences (Nasdaq: SAVA), una empresa biotecnológica en etapa clínica centrada en la enfermedad de Alzheimer, ha anunciado una conferencia telefónica programada para jueves 8 de agosto de 2024, a las 8:30 a.m. hora del Este. La llamada tiene como objetivo discutir desarrollos recientes y proporcionar una actualización de la empresa.
Las partes interesadas pueden acceder a la transmisión de audio a través del sitio web de la empresa o mediante un enlace directo. Una repetición de la transmisión estará disponible durante 90 días después del evento en la página de Presentaciones de la Empresa de Cassava Sciences.
Este anuncio sugiere que Cassava Sciences podría tener actualizaciones significativas para compartir sobre su investigación en Alzheimer o el progreso de la empresa, lo que podría impactar el rendimiento de sus acciones.
카사바 사이언스(Cassava Sciences) (Nasdaq: SAVA), 알츠하이머병에 집중하는 임상 단계의 생명공학 회사가 2024년 8월 8일 목요일 동부 표준시 기준 오전 8시 30분에 예정된 전화 회의를 발표했습니다. 이 전화 통화의 목적은 최근 발전에 대해 논의하고 회사 업데이트를 제공하는 것입니다.
관심 있는 분들은 회사 웹사이트를 통해 오디오 웹캐스트에 접속하거나 직접 링크를 통해 접속할 수 있습니다. 이벤트 이후 90일 동안 웹캐스트 재생이 가능하며, 카사바 사이언스의 회사 발표 페이지에서 확인하실 수 있습니다.
이번 발표는 카사바 사이언스가 알츠하이머 연구나 회사 진행 상황에 대한 중요한 업데이트를 공유할 가능성을 나타내며, 이는 주식 성과에 영향을 미칠 수 있습니다.
Cassava Sciences (Nasdaq: SAVA), une entreprise de biotechnologie en phase clinique axée sur la maladie d'Alzheimer, a annoncé une conférence téléphonique prévue pour jeudi 8 août 2024, à 8h30, heure de l'Est. L'appel vise à discuter des développements récents et à fournir une mise à jour de l'entreprise.
Les parties intéressées peuvent accéder à la diffusion audio par le biais du site Web de l'entreprise ou via un lien direct. Un replay de la diffusion sera disponible pendant 90 jours après l'événement sur la page des Présentations de l'Entreprise de Cassava Sciences.
Cette annonce suggère que Cassava Sciences pourrait avoir des mises à jour significatives à partager concernant ses recherches sur Alzheimer ou les progrès de l'entreprise, ce qui pourrait avoir un impact sur la performance de ses actions.
Cassava Sciences (Nasdaq: SAVA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Alzheimer-Krankheit konzentriert, hat eine Konferenzschaltung für Donnerstag, den 8. August 2024, um 8:30 Uhr Eastern Time angekündigt. Ziel des Anrufs ist es, neue Entwicklungen zu besprechen und ein Unternehmensupdate zu geben.
Interessierte Parteien können über die Unternehmenswebsite oder einen direkten Link auf das Audio-Webcast zugreifen. Eine Aufzeichnung des Webcasts wird für 90 Tage nach der Veranstaltung auf der Seite der Unternehmenspräsentationen von Cassava Sciences verfügbar sein.
Diese Ankündigung deutet darauf hin, dass Cassava Sciences möglicherweise bedeutende Neuigkeiten zu ihrer Alzheimer-Forschung oder Fortschritten im Unternehmen hat, die sich auf ihre Aktienperformance auswirken könnten.
- None.
- None.
AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time.
| Event details follow: | |
| Date: | Thursday, August 8th |
| Time: | 8:30 a.m. Eastern Time |
| Audio Webcast: | https://www.CassavaSciences.com/company-presentations |
| Or | |
| Audio Webcast: | https://edge.media-server.com/mmc/p/zjvmjjcr |
A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences’ website for 90 days following the webcast.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450 or ESchoen@CassavaSciences.com
FAQ
When is Cassava Sciences (SAVA) holding its conference call to discuss recent developments?
How can investors access Cassava Sciences' (SAVA) upcoming conference call?
What is the main focus of Cassava Sciences' (SAVA) research?
How long will the replay of Cassava Sciences' (SAVA) August 8th, 2024 conference call be available?
